# Standard BioTools > Mediated Wiki article. Canonical URL: https://mediated.wiki/source/Standard_BioTools > Markdown URL: https://mediated.wiki/source/Standard_BioTools.md > Source: https://en.wikipedia.org/wiki/Standard_BioTools > Source revision: 1344578235 > License: Creative Commons Attribution-ShareAlike 4.0 International (https://creativecommons.org/licenses/by-sa/4.0/) {{Short description|American life science tools company}} {{Redirect|FLDM|the school in Nuevo León, Mexico|Nuevo León#Education}} {{Infobox company | name = Standard BioTools Inc. | former_names = {{ubl|Fluidigm Corporation| Mycometrix}} | founded = {{start date and age|1999}} | key_people = Michael Egholm ([president](/source/President_(corporate_title)) & [CEO](/source/Chief_executive_officer)) | type = [Public](/source/Public_company) | traded_as = {{ubl|{{NASDAQ|LAB}}|[Russell 2000](/source/Russell_2000) component}} | hq_location_city = [Boston, Massachusetts](/source/Boston%2C_Massachusetts) | hq_location_country = United States | revenue = {{decrease}} {{US$|85 million|link=yes}} (2025){{Cite web |url=https://www.sec.gov/ix?doc=/Archives/edgar/data/0001162194/000119312526108326/lab-20251231.htm |title=2025 Annual Report (Form 10-K) |date=March 16, 2026 |publisher=U.S. Securities and Exchange Commission}} | num_employees = 615 (2025) | website = {{url|https://standardbio.com}} }} thumb|Standard BioTools Canada '''Standard BioTools Inc.''', previously known as '''Fluidigm Corp.''', is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or [integrated fluidic circuits (IFCs)](/source/Integrated_fluidic_circuit),{{Cite web |last=Dutton |first=Gail |date=2015-01-14 |title=Fluidigm Pioneers Single-Cell Biology |url=https://www.genengnews.com/news/fluidigm-pioneers-single-cell-biology/ |access-date=2023-12-11 |website=GEN - Genetic Engineering and Biotechnology News |language=en-US}} and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications. Standard BioTools sells products to academic research institutions; translational research and medical centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology and plant and animal research companies; and contract research organizations. ==Business model== Standard BioTools is a public company traded on the [Nasdaq](/source/Nasdaq) stock exchange, previously under the ticker symbol FLDM,{{Cite web |last=Tse |first=Andrea |date=2011-02-10 |title=Fluidigm Pops After IPO |url=https://www.thestreet.com/investing/stocks/fluidigm-pops-after-ipo-11004250 |access-date=2023-12-11 |website=TheStreet |language=en-us}} currently under [https://www.nasdaq.com/market-activity/stocks/fldm LAB]. Its genomic analysis products create [microfluidic devices](/source/Microfluidic_device) or IFCs.{{Cite journal |date=7 Sep 2009 |title=Fluidigm: 250 Million Microfluidic Valves Manufactured – and Counting |url=http://www.highbeam.com/doc/1G1-207191411.html |archive-url=https://web.archive.org/web/20150402104340/http://www.highbeam.com/doc/1G1-207191411.html |archive-date=2 April 2015 |website=Nanotechnology Business Journal}}{{Cite web |date=9 January 2014 |title=Fluidigm and DVS Sciences Announce Agreement for Fluidigm to Acquire DVS Sciences – Creating a Single-Cell Technology Powerhouse |url=https://investors.standardbio.com/news-releases/news-release-details/fluidigm-acquire-dvs-sciences |website=Standard BioTools Press Release}} Genomics applications using IFCs processed on the Biomark™ X9 System for High-Throughput Genomics include gene expression and genotyping by PCR and NGS library preparation for pathogen detection, agrigenomics, sample identification and pharmacogenomics. Its proteomic analysis products are based on technology developed by DVS Sciences, acquired by Fluidigm® in 2014. DVS is best known for its multiparameter single-cell protein analysis systems,{{Cite web |date=4 May 2013 |title=Dvs Sciences Introduces The Cytof® 2 |url=https://investors.standardbio.com/news-releases/news-release-details/dvs-sciences-introduces-cytofr-2 |website=Standard BioTools Press Release}} which analyze antibody/metal complexes using atomic mass spectrometry. The technology enables precise, high-parameter single-cell protein analysis for applications in life sciences research. The company has remained a pioneer in integrated microfluidic technology, with continued iterations of IFCs for a growing variety of applications.{{cn|date=January 2024}} It is also the only company developing mass cytometry technologies for both flow cytometry and imaging applications.{{cn|date=January 2024}} ==History== The company was founded in 1999 as Mycometrix by [Stephen Quake](/source/Stephen_Quake) and Gajus Worthington.{{Cite web |date=4 June 2001 |title=Mycometrix changes name to Fluidigm |url=https://www.drugdiscoveryonline.com/doc/mycometrix-changes-name-to-fluidigm-0001 |access-date=2023-12-11 |website=Drug Discovery Online}} The company was formed to commercialize technology developed by Quake at the [California Institute of Technology](/source/California_Institute_of_Technology) referred to as microfluidic large-scale integration and branded IFCs[1]. Richard DeLateur, a 20-year veteran of [Intel](/source/Intel), came on as chief financial officer in 2006.{{Cite news |last=Del Conte |first=Natali T. |date=20 March 2006 |title=Richard DeLateur and Fludigm |pages=17 |work=The San Francisco Examiner |url=https://www.newspapers.com/article/the-san-francisco-examiner-richard-delat/108064922/ |access-date=2023-12-11}} Worthington was the company’s chief executive officer from its inception in 1999 to 2016. Quake has remained a member of the company’s scientific advisory board. The company’s founders created integrated circuits that carried fluids rather than electrons. In 2009, the company was described as “the world’s leading manufacturer of microfluidic devices.” The company’s original microfluidics products were aimed for use in applications such as [protein crystallization](/source/protein_crystallization), [genotyping](/source/genotyping), [DNA analysis](/source/DNA_analysis) and [PCR](/source/Polymerase_chain_reaction). The company completed a successful [initial public offering](/source/initial_public_offering) (IPO) in February 2011, raising about $75 million. This followed a failed, ill-timed IPO in 2008.{{Cite web |date=22 September 2008 |title=Fluidigm postpones IPO, citing market conditions |url=https://www.reuters.com/article/fluidigm-ipo-idINN1853313020080922/ |website=Reuters}} As of the 2011 IPO, Fluidigm had not yet become profitable. Following a $250 million investment from Casdin Capital, LLC and [Viking Global Investors](/source/Viking_Global_Investors) LP in April 2022, Fluidigm changed its name to Standard BioTools.{{Cite web |date=4 April 2022 |title=Fluidigm Completes $250 Million Strategic Capital Infusion and Changes Name to Standard BioTools Inc |url=https://investors.fluidigm.com/news-releases/news-release-details/fluidigm-completes-250-million-strategic-capital-infusion-and |website=Standard BioTools Press Release}} This change in name emphasized their mission to create a diversified, scalable innovation-focused life science tools company serving the pharma research markets.{{Cite web |date=19 April 2024 | title=New Name, New Investment, and New CEO for Fluidigm |url=https://www.mddionline.com/business/new-name-new-investment-and-new-ceo-for-fluidigm |website=Meddionline}} The company acquired Nasdaq-listed [SomaLogic](/source/SomaLogic) in January 2024 in an all-stock deal.{{cite press release |url=https://www.globenewswire.com/en/news-release/2023/10/04/2754537/0/en/Standard-BioTools-and-SomaLogic-to-Combine-in-All-Stock-Merger-Creating-a-Diversified-Leader-in-Life-Sciences-Tools.html |title= Standard BioTools and SomaLogic to Combine in All-Stock Merger Creating a Diversified Leader in Life Sciences Tools |date=October 4, 2023 |agency=[GlobeNewswire](/source/GlobeNewswire)}} ==Operations== At the end of 2023, Standard BioTools had a headcount of 500 personnel. In addition to its headquarters and laboratory facility in South San Francisco, California, which it expanded in 2014, the company established the first [biochip](/source/biochip) manufacturing facility in Singapore in 2005. In 2022, Standard BioTools expanded their offices and manufacturing and research and development facility in Markham, Ontario.{{cn|date=January 2024}} ==Notes== {{Reflist|33em}} ==References== {{refbegin|}} * {{cite book |last=Angelescu |first=Dan E. |date=2011 |title=Highly Integrated Microfluidics Design |chapter=5.3.1 Microfluidic Large-Scale Integration: Fludigm |series=Integrated Microsystems |publisher=[Artech House](/source/Artech_House) |url=https://books.google.com/books?id=M0S64KXpUtMC |via=[Google Books](/source/Google_Books) |isbn=9781596939806}} ''Note: the book version viewed did not include the entire chapter cited here, only pages 225, 226 and 227.'' * {{cite web |last1=Linthwaite |first1=Stephen Christopher |last2=Jog |first2=Vikram |url=https://www.sec.gov/ix?doc=/Archives/edgar/data/1162194/000116219422000021/fldm-20211231.htm |title=Fluidigm Corporation 2021 Annual Report (Form 10-K) |date=8 March 2022 |publisher=[U.S. Securities and Exchange Commission](/source/U.S._Securities_and_Exchange_Commission) |type=XBRL}} {{refend}} ==External links== {{Commons category|position=left}} {{Authority control}} Category:Research support companies Category:Technology companies based in the San Francisco Bay Area Category:Companies based in South San Francisco, California Category:American companies established in 1999 Category:Technology companies established in 1999 Category:1999 establishments in California Category:2011 initial public offerings Category:Companies listed on the Nasdaq --- Adapted from the Wikipedia article [Standard BioTools](https://en.wikipedia.org/wiki/Standard_BioTools) by Wikipedia contributors ([contributor history](https://en.wikipedia.org/wiki/Standard_BioTools?action=history)). Available under [Creative Commons Attribution-ShareAlike 4.0 International](https://creativecommons.org/licenses/by-sa/4.0/). Changes may have been made.